ME02754B - Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme - Google Patents
Ligandi opioidnih receptora i postupci njihove upotrebe i pripremeInfo
- Publication number
- ME02754B ME02754B MEP-2017-129A MEP2017129A ME02754B ME 02754 B ME02754 B ME 02754B ME P2017129 A MEP2017129 A ME P2017129A ME 02754 B ME02754 B ME 02754B
- Authority
- ME
- Montenegro
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- compound
- compound according
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 3
- 102000003840 Opioid Receptors Human genes 0.000 title 1
- 108090000137 Opioid Receptors Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 20
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 14
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (20)
1. Jedinjenje formule IV-1, ili neka njegova farmaceutski prihvatljiva so,: u kojoj: R21 i R22 su nezavisno H ili CH3; A4 je neki opciono supstituisan cikl formule C(CH2)n, u kojoj n = 2-5, pri čemu je opciona supstitucija halo, cijano, C1-C6 alkil, C1-C6 razgranat alkil, halogenovan C1-C6 alkil, hidroksil, C1-C6 alkiloksi, amino, ili C1-C6 alkilamino; B3 je H ili neki opciono supstituisan C1-C6 alkil, pri čemu je opciona supstitucija halo, hidroksi ili C1-C6 alkoksi; B4 je C1-C6 alkilen; D1 je neki opciono supstituisan monociklični ili biciklični aril ili heteroaril, u kom je svaki prsten neki 5, 6 ili 7-člani prsten, a opciona supstitucija je halo, cijano, C1-C6 alkil, C1-C6 razgranat alkil, halogenovan C1-C6 alkil, hidroksil, C1-C6 alkiloksi, amino, ili C1-C6 alkilamino; i B5 je neki opciono supstituisan monociklični ili biciklični aril ili heteroaril, u kom je svaki prsten neki 5, 6, ili 7-člani prsten, a opciona supstitucija je halo, cijano, C1-C6 alkil, C1-C6 razgranat alkil, halogenovan C1-C6 alkil, hidroksil, C1-C6 alkiloksi, amino, ili C1-C6 alkilamino.
2.Jedinjenje prema zahtevu 1, ili neka njegova farmaceutski prihvatljiva so, koje ima strukturu formule VIII: u kojoj su R26 i R27 nezavisno H ili neki njegov izotop.
3.Jedinjenje prema zahtevu 2, ili neka njegova farmaceutski prihvatljiva so, pri čemu jedinjenje ima formulu IX
4.Jedinjenje prema zahtevima 2 ili 3, ili neka njegova farmaceutski prihvatljiva so, pri čemu jedinjenje ima formulu VII-l
5.Jedinjenje prema nekom od zahteva 2-4, ili neka njegova farmaceutski prihvatljiva so, pri čemu jedinjenje ima formulu X
6. Jedinjenje prema nekom od zahteva 1-5, ili neka njegova farmaceutski prihvatljiva so, kod kog je D1 neki opciono supstituisan fenil, pri čemu je opciona supstitucija halo, cijano, C1-C6 alkil, C1-C6 razgranat alkil, halogenovan C1-C6 alkil, hidroksil, C1-C6 alkiloksi, amino, ili C1-C6 alkilamino ili neki opciono supstituisan piridil, pri čemu je opciona supstitucija halo, cijano, C1-C6 alkil, C1-C6 razgranat alkil, halogenovan C1-C6 alkil, hidroksil, C1-C6 alkiloksi, amino, ili C1-C6 alkilamino.
7.Jedinjenje prema nekom od zahteva 1-5, ili neka njegova farmaceutski prihvatljiva so, kod kog je B5 neki opciono supstituisan monociklični ili biciklični heteroaril, u kom je svaki prsten neki 5, 6, ili 7- člani prsten, a opciona supstitucija je halo, cijano, C1-C6 alkil, C1-C6 razgranat alkil, halogenovan C1-C6alkil, hidroksil, C1-C6 alkiloksi, amino, ili C1-C6 alkilamino.
8.Jedinjenje prema nekom od zahteva 1-5, ili neka njegova farmaceutski prihvatljiva so, kod kog je B5 neki opciono supstituisan aril ili heteroaril odabran iz grupe koju čine pri čemu je opciona supstitucija halo, cijano, C1-C6 alkil, C1-C6 razgranat alkil, halogenovan C1-C6 alkil, hidroksil, C1-C6 alkiloksi, amino, ili C1-C6 alkilamino.
9.Jedinjenje prema zahtevima 1-5, ili neka njegova farmaceutski prihvatljiva so, kod kog je B5 odabran iz grupe koju čine u kojima R23, R24, i R30 su svaki nezavisno nula, H, OH, halo, razgranat ili nerazgranat C1-C6 alkil, cijano, C1-C6alkoksi, amino, C1-C6 haloalkil, ili, R23 i R24 zajedno obrazuju neki aril, heteroaril ili ciki koji je vezan za jedan ili više atoma B5; a R25 je H ili neki opciono supstituisan razgranat ili nerazgranat alkil, pri čemu je opciona supstitucija halo, hidroksi ili C1-C3 alkoksi.
10.Jedinjenje prema zahtevu 9, ili neka njegova farmaceutski prihvatljiva so, kod kog su R23, R24, i R30 svaki nezavisno H, NH2, OH, CI, Br, F, I, OMe, CN, ili CH3.
11.Jedinjenje prema zahtevu 9, ili neka njegova farmaceutski prihvatljiva so, kod kog B5 predstavlja
12.Jedinjenje prema zahtevu 9 ili 11, ili neka njegova farmaceutski prihvatljiva so, kod kog R23 predstavlja C1-C6 alkoksi.
13.Jedinjenje prema nekom od zahteva 1-12, ili neka njegova farmaceutski prihvatljiva so, kod kog B3 predstavlja H ili C1-C6 alkil.
14.Jedinjenje prema zahtevu 1, ili neka njegova farmaceutski prihvatljiva so, koje ima formulu:
15.Jedinjenje prema zahtevu 1, ili neka njegova farmaceutski prihvatljiva so, koje ima formulu:
16.Jedinjenje prema zahtevu 1, ili neka njegova farmaceutski prihvatljiva so, koje ima formulu:
17.Jedinjenje prema zahtevu 1, ili neka njegova farmaceutski prihvatljiva so, koje ima formulu:
18.Farmaceutska kompozicija koja obuhvata jedinjenje, ili neku njegovu farmaceutski prihvatljivu so, prema bilo kom od zahteva 1-17 i neki farmaceutski prihvatljiv nosač.
19.Jedinjenje ili neka njegova farmaceutski prihvatljiva so, ili kompozicija prema bilo kom od zahteva 1-18 za upotrebu u tretiranju bola.
20. Postupak pripreme jedinjenja, ili neke njegove farmaceutski prihvatljive soli, prema zahtevu 2, gde R26 i R27 predstavljaju H, pri čemu taj postupak obuhvata: dovođenje u kontakt pod pogodnim uslovima za obrazovanje jedinjenja koje ima strukturu pod pogodnim uslovima za obrazovanje jedinjenja koje ima strukturu
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161466809P | 2011-03-23 | 2011-03-23 | |
| US201261596808P | 2012-02-09 | 2012-02-09 | |
| EP12760456.9A EP2688403B1 (en) | 2011-03-23 | 2012-03-23 | Opioid receptor ligands and methods of using and making same |
| PCT/US2012/030327 WO2012129495A1 (en) | 2011-03-23 | 2012-03-23 | Opioid receptor ligands and methods of using and making same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02754B true ME02754B (me) | 2018-01-20 |
Family
ID=46877853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-129A ME02754B (me) | 2011-03-23 | 2012-03-23 | Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US8835488B2 (me) |
| EP (3) | EP3872076A1 (me) |
| JP (6) | JP5912169B2 (me) |
| KR (3) | KR101991327B1 (me) |
| CN (1) | CN103702561B (me) |
| AU (2) | AU2012230761B2 (me) |
| CA (1) | CA2830742C (me) |
| CY (1) | CY1119057T1 (me) |
| DK (2) | DK2688403T3 (me) |
| EA (1) | EA025456B1 (me) |
| ES (2) | ES2857549T3 (me) |
| HR (1) | HRP20171021T1 (me) |
| HU (2) | HUE054055T2 (me) |
| IL (4) | IL228506A (me) |
| LT (1) | LT2688403T (me) |
| ME (1) | ME02754B (me) |
| PL (2) | PL3290415T3 (me) |
| PT (2) | PT3290415T (me) |
| RS (1) | RS56111B1 (me) |
| SI (1) | SI2688403T1 (me) |
| SM (1) | SMT201700325T1 (me) |
| WO (1) | WO2012129495A1 (me) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME02754B (me) | 2011-03-23 | 2018-01-20 | Trevena Inc | Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme |
| ES2553449T3 (es) | 2011-07-06 | 2015-12-09 | Gilead Sciences, Inc. | Compuestos para el tratamiento de VIH |
| TWI706945B (zh) | 2013-03-01 | 2020-10-11 | 美商基利科學股份有限公司 | 供治療反轉錄病毒科病毒感染之治療性化合物 |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| EP3350166A4 (en) | 2015-09-16 | 2019-05-01 | Metacrine, Inc. | FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF |
| CA2998493A1 (en) | 2015-09-16 | 2017-03-23 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| WO2017049172A1 (en) | 2015-09-16 | 2017-03-23 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| HUE048032T2 (hu) * | 2015-10-15 | 2020-05-28 | Jiangsu Hengrui Medicine Co | Oxaspiro-származék, elõállítási eljárása és alkalmazásai gyógyszerekben |
| CN106588899B (zh) * | 2015-10-15 | 2019-11-15 | 江苏恒瑞医药股份有限公司 | 吡啶基取代的6-氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用 |
| US10588889B2 (en) * | 2015-12-14 | 2020-03-17 | Trevena, Inc. | Methods of treating hyperalgesia |
| WO2017105881A1 (en) * | 2015-12-15 | 2017-06-22 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating pain |
| HK1254673A1 (zh) * | 2015-12-17 | 2019-07-26 | Trevena, Inc. | 阿片受体配体和细胞色素p450抑制剂 |
| CN107098876B (zh) * | 2016-02-23 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用 |
| CA3029768C (en) | 2016-07-01 | 2022-05-17 | NeuForm Pharmaceuticals, Inc. | Deuterated oliceridine compounds and pharmaceutical compositions thereof useful for treating pain |
| SI3347352T1 (sl) | 2016-08-19 | 2019-08-30 | Gilead Sciences, Inc. | Terapevtske spojine uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom HIV |
| EP3555072A1 (en) * | 2016-12-16 | 2019-10-23 | Esteve Pharmaceuticals, S.A. | Tetrahydropyran and tetrahydrothiopyran amide derivatives having multimodal activity against pain |
| KR102662065B1 (ko) * | 2017-02-17 | 2024-05-07 | 트레베나, 인코포레이티드. | 7-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법 |
| WO2018152293A1 (en) | 2017-02-17 | 2018-08-23 | Trevena, Inc. | 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
| EP4596041A3 (en) | 2017-03-15 | 2025-12-10 | Eli Lilly and Company | Farnesoid x receptor agonists and uses thereof |
| JP7174709B2 (ja) | 2017-03-15 | 2022-11-17 | メタクリン，インク． | ファルネソイドｘ受容体アゴニストおよびその使用 |
| BR112019021447A2 (pt) * | 2017-04-14 | 2020-05-05 | Jiangsu Hengrui Medicine Co | sal fumarato, forma cristalina i do referido sal, métodos para preparação dos mesmos, composição farmacêutica compreendendo o sal e a forma cristalina i e uso do sal fumarato, da forma cristalina i e da composição farmacêutica |
| CN108727347B (zh) * | 2017-04-14 | 2020-06-16 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的晶型及其制备方法 |
| BR112019020691A2 (pt) * | 2017-04-14 | 2020-05-12 | Jiangsu Hengrui Medicine Co., Ltd. | Composição farmacêutica contendo agonista do mor e agonista do kor, e usos da mesma |
| CN109206417B (zh) * | 2017-07-04 | 2023-01-03 | 四川海思科制药有限公司 | 阿片受体激动剂及其应用 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| CN109516982B (zh) * | 2017-09-18 | 2022-08-23 | 上海华汇拓医药科技有限公司 | μ-阿片受体激动剂及其制备方法和在医药领域的应用 |
| MX395589B (es) | 2017-09-28 | 2025-03-25 | Jiangsu Hengrui Medicine Co | Método para preparar derivado de oxaespirociclo e intermediario del mismo. |
| CN111148515B (zh) * | 2017-10-13 | 2022-07-19 | 山东绿叶制药有限公司 | 2,6-二氧杂螺[4,5]癸烷类衍生物、其制备方法及其在医药上的应用 |
| JP2021505547A (ja) | 2017-12-06 | 2021-02-18 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 疼痛を治療するための薬物の製造におけるｍｏｒアゴニストと組み合わせたｋｏｒアゴニストの使用 |
| JP2021512952A (ja) | 2018-02-05 | 2021-05-20 | アルカームス・インコーポレイテッド | 疼痛の処置のための化合物 |
| JP7083398B2 (ja) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジン誘導体およびｈｉｖ感染を処置するためのその使用 |
| KR102847339B1 (ko) | 2018-02-16 | 2025-08-19 | 길리애드 사이언시즈, 인코포레이티드 | 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체 |
| CN111836807A (zh) * | 2018-04-28 | 2020-10-27 | 四川科伦博泰生物医药股份有限公司 | 氧杂螺环类化合物及其制备方法和用途 |
| TW202015678A (zh) * | 2018-05-14 | 2020-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種ｍｏｒ受體激動劑醫藥組成物 |
| CA3103522C (en) | 2018-07-16 | 2023-11-21 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
| KR20250073553A (ko) | 2018-09-18 | 2025-05-27 | 일라이 릴리 앤드 캄파니 | 파르네소이드 x 수용체 효능제 및 그의 용도 |
| CN112638907B (zh) * | 2018-10-12 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 |
| CN112638906B (zh) * | 2018-10-12 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 |
| WO2020147848A1 (zh) * | 2019-01-17 | 2020-07-23 | 上海海雁医药科技有限公司 | 三环取代的氧杂螺环衍生物、其制法与医药上的用途 |
| CN111662284B (zh) * | 2019-03-06 | 2021-08-10 | 上海海雁医药科技有限公司 | 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途 |
| TW202519228A (zh) | 2019-11-26 | 2025-05-16 | 美商基利科學股份有限公司 | 預防hiv之蛋白殼抑制劑 |
| EP4092032A4 (en) | 2020-01-17 | 2024-02-28 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Optically pure oxaspiro-substituted pyrrolopyrazole derivative, preparation method therefor and pharmaceutical use thereof |
| CN113412263B (zh) | 2020-01-17 | 2024-07-26 | 上海海雁医药科技有限公司 | 氮杂双环取代的氧杂螺环衍生物、其制法与医药上的用途 |
| CN113214264B (zh) * | 2020-01-21 | 2022-08-09 | 上海海雁医药科技有限公司 | 二氢吡咯并五元杂芳基取代的氧杂螺环衍生物、其制法与医药上的用途 |
| CA3171987A1 (en) | 2020-03-18 | 2021-09-23 | Nicholas D. Smith | Crystalline forms of a farnesoid x receptor agonist |
| US12491160B2 (en) | 2020-03-18 | 2025-12-09 | Eli Lilly And Company | Formulations of a farnesoid X receptor agonist |
| EP4172157B1 (en) | 2020-06-25 | 2025-11-19 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
| CN114269738B (zh) * | 2020-08-10 | 2023-09-29 | 成都苑东生物制药股份有限公司 | 一种mor受体激动剂化合物、制备方法及其用途 |
| CN112694485B (zh) * | 2020-09-10 | 2023-04-07 | 四川海品信医药科技有限公司 | 一种阿片受体激动剂噻吩类化合物及其制备方法 |
| JP7751645B2 (ja) | 2020-12-29 | 2025-10-08 | 上海海雁医薬科技有限公司 | オキシスピロ環置換ピロロピラゾール誘導体及びその中間体並びにその調製方法 |
| WO2023284788A1 (zh) | 2021-07-13 | 2023-01-19 | 上海海雁医药科技有限公司 | Mor受体激动剂的药学上可接受的盐、其多晶型物及其用途 |
| CN115677675B (zh) * | 2021-07-21 | 2025-09-12 | 成都苑东生物制药股份有限公司 | 一种6-氧杂螺[4,5]癸烷类化合物的盐、制备方法及用途 |
| IL310506A (en) * | 2021-08-02 | 2024-03-01 | Shujing Biopharma Co Ltd | An oxaspiro derivative, a method for its preparation and use |
| WO2023030319A1 (zh) * | 2021-08-31 | 2023-03-09 | 天地恒一制药股份有限公司 | 阿片受体激动剂及其制备方法和用途 |
| PL4445900T3 (pl) | 2021-12-03 | 2025-09-22 | Gilead Sciences, Inc. | Związki terapeutyczne przeciwko zakażeniu wirusem hiv |
| WO2023102529A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| KR20240113832A (ko) | 2021-12-03 | 2024-07-23 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염 치료용 화합물 |
| CN116041336B (zh) * | 2022-01-21 | 2024-07-09 | 成都硕德药业有限公司 | 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法 |
| CN116589451B (zh) * | 2022-02-11 | 2024-07-09 | 成都硕德药业有限公司 | 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法 |
| CN118638109B (zh) * | 2024-04-30 | 2025-10-28 | 中山大学 | 一种阿片类药物-奥赛利定的制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5825980B2 (ja) | 1976-02-12 | 1983-05-31 | ヤマサ醤油株式会社 | サイクリックヌクレオチドの定量法 |
| US4602035A (en) * | 1983-12-07 | 1986-07-22 | Hoechst-Roussel Pharmaceuticals Inc. | Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines |
| US5223530A (en) | 1990-07-31 | 1993-06-29 | Sri, International | Arylcycloalkanepolyalkylamine ligands |
| US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
| AU3192295A (en) * | 1994-08-11 | 1996-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Substituted amine derivative and medicinal composition containing the same |
| ATE301457T1 (de) | 1995-06-12 | 2005-08-15 | Searle & Co | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
| US6071918A (en) | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
| GB0130261D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Lactams as tachykinin antagonists |
| TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| SI2208727T1 (sl) | 2002-09-19 | 2012-11-30 | Lilly Co Eli | Diaril etri kot antagonisti opioidnega receptorja |
| KR101255074B1 (ko) * | 2003-10-01 | 2013-04-16 | 아돌로 코포레이션 | 스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법 |
| WO2007041341A2 (en) * | 2005-09-29 | 2007-04-12 | The Trustees Of Columbia University In The City Of New York | Identification of anti-cancer compounds and compounds for treating huntington's disease and methods of treatment thereof |
| US20070203224A1 (en) * | 2006-01-09 | 2007-08-30 | University Of Southern California | Small-molecules for treating cancer and abnormal cell proliferation disorders |
| US7645767B2 (en) | 2006-08-31 | 2010-01-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
| JP2010508358A (ja) * | 2006-11-01 | 2010-03-18 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用 |
| WO2008057856A2 (en) * | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
| US20090028873A1 (en) | 2007-07-27 | 2009-01-29 | Auspex Pharmaceuticals, Inc. | Substituted cyclohexanols |
| PL2260042T3 (pl) * | 2008-03-27 | 2012-02-29 | Gruenenthal Gmbh | Podstawione spirocykliczne pochodne cykloheksanu |
| FR2939136B1 (fr) * | 2008-12-02 | 2010-12-03 | Galderma Res & Dev | Nouveaux composes 4-(heterocycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| FR2967672B1 (fr) * | 2010-11-22 | 2012-12-28 | Sanofi Aventis | Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques |
| ME02754B (me) * | 2011-03-23 | 2018-01-20 | Trevena Inc | Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme |
| US10588889B2 (en) | 2015-12-14 | 2020-03-17 | Trevena, Inc. | Methods of treating hyperalgesia |
-
2012
- 2012-03-23 ME MEP-2017-129A patent/ME02754B/me unknown
- 2012-03-23 CN CN201280021050.7A patent/CN103702561B/zh active Active
- 2012-03-23 PT PT171734833T patent/PT3290415T/pt unknown
- 2012-03-23 PL PL17173483T patent/PL3290415T3/pl unknown
- 2012-03-23 DK DK12760456.9T patent/DK2688403T3/en active
- 2012-03-23 ES ES17173483T patent/ES2857549T3/es active Active
- 2012-03-23 SM SM20170325T patent/SMT201700325T1/it unknown
- 2012-03-23 KR KR1020137027288A patent/KR101991327B1/ko active Active
- 2012-03-23 KR KR1020187025108A patent/KR101991326B1/ko active Active
- 2012-03-23 KR KR1020197016977A patent/KR102129247B1/ko active Active
- 2012-03-23 EP EP20217112.0A patent/EP3872076A1/en not_active Withdrawn
- 2012-03-23 AU AU2012230761A patent/AU2012230761B2/en not_active Ceased
- 2012-03-23 PL PL12760456T patent/PL2688403T3/pl unknown
- 2012-03-23 CA CA2830742A patent/CA2830742C/en active Active
- 2012-03-23 LT LTEP12760456.9T patent/LT2688403T/lt unknown
- 2012-03-23 WO PCT/US2012/030327 patent/WO2012129495A1/en not_active Ceased
- 2012-03-23 SI SI201231000T patent/SI2688403T1/sl unknown
- 2012-03-23 HR HRP20171021TT patent/HRP20171021T1/hr unknown
- 2012-03-23 DK DK17173483.3T patent/DK3290415T3/da active
- 2012-03-23 RS RS20170630A patent/RS56111B1/sr unknown
- 2012-03-23 EA EA201391332A patent/EA025456B1/ru unknown
- 2012-03-23 EP EP17173483.3A patent/EP3290415B1/en active Active
- 2012-03-23 EP EP12760456.9A patent/EP2688403B1/en active Active
- 2012-03-23 US US13/428,849 patent/US8835488B2/en active Active
- 2012-03-23 HU HUE17173483A patent/HUE054055T2/hu unknown
- 2012-03-23 HU HUE12760456A patent/HUE032948T2/en unknown
- 2012-03-23 JP JP2014501273A patent/JP5912169B2/ja active Active
- 2012-03-23 ES ES12760456.9T patent/ES2632009T3/es active Active
- 2012-03-23 PT PT127604569T patent/PT2688403T/pt unknown
-
2013
- 2013-08-12 US US13/964,505 patent/US9044469B2/en active Active
- 2013-09-17 IL IL228506A patent/IL228506A/en active IP Right Grant
-
2015
- 2015-05-15 US US14/712,974 patent/US9309234B2/en active Active
- 2015-12-27 IL IL243318A patent/IL243318B/en active IP Right Grant
-
2016
- 2016-03-30 JP JP2016067208A patent/JP6243949B2/ja not_active Expired - Fee Related
- 2016-04-07 US US15/093,315 patent/US9642842B2/en active Active
-
2017
- 2017-02-03 AU AU2017200745A patent/AU2017200745B2/en not_active Ceased
- 2017-03-29 US US15/472,345 patent/US9849119B2/en active Active
- 2017-07-04 CY CY20171100716T patent/CY1119057T1/el unknown
- 2017-11-09 JP JP2017216012A patent/JP6649341B2/ja not_active Expired - Fee Related
- 2017-12-01 US US15/828,695 patent/US11077098B2/en active Active
-
2019
- 2019-07-25 US US16/522,008 patent/US10588898B2/en active Active
-
2020
- 2020-01-15 JP JP2020004039A patent/JP6923683B2/ja active Active
- 2020-01-21 IL IL272165A patent/IL272165B/en unknown
-
2021
- 2021-06-27 IL IL284407A patent/IL284407B2/en unknown
- 2021-07-02 US US17/367,021 patent/US11931350B2/en active Active
- 2021-07-28 JP JP2021122940A patent/JP7248750B2/ja active Active
-
2023
- 2023-03-15 JP JP2023040218A patent/JP2023075282A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02754B (me) | Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme | |
| JP2016504365A5 (me) | ||
| JP2013533884A5 (me) | ||
| RU2019133646A (ru) | Изохинолины в качестве ингибиторов hpk1 | |
| JP2013530238A5 (me) | ||
| JP2016510758A5 (me) | ||
| RU2013153388A (ru) | Способы применения активаторов пируваткиназы | |
| NZ718487A (en) | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof | |
| RU2018105549A (ru) | Производные бензодиазепина как ингибиторы rsv | |
| JP2013533883A5 (me) | ||
| RU2014140735A (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| RU2016106003A (ru) | Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| CO6321289A2 (es) | Compuestos de ester boronato y composiciones farmaceuticas de los mismos | |
| RU2014130125A (ru) | Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| JP2018515492A5 (me) | ||
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| RU2017104856A (ru) | Функционализированные и замещенные индолы в качестве противораковых средств | |
| JP2014506599A5 (me) | ||
| JP2013503139A5 (me) | ||
| JP2016500661A5 (me) | ||
| JP2014508811A5 (me) | ||
| ME02672B (me) | Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament | |
| JP2017509689A5 (me) | ||
| MD4583B1 (ro) | Piridinone biciclice noi | |
| RU2012125971A (ru) | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных |